Aurinia Pharmaceuticals (AUPH)
16.07
-0.01 (0.06%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd.
August 26, 2026 9:25 PM - SEC Filing
Form 4 Aurinia Pharmaceuticals For: Aug 21 Filed by: Robertson Stephen P.
August 25, 2026 9:29 PM - SEC Filing
Form 8-K Aurinia Pharmaceuticals For: Aug 19
August 25, 2026 7:03 PM - SEC Filing
Form 144 Aurinia Pharmaceuticals Filed by: Robertson Stephen P.
August 21, 2026 8:55 PM - SEC Filing
Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
August 20, 2026 8:38 AM - StreetInsider
Form 8-K Aurinia Pharmaceuticals For: Aug 19
August 19, 2026 4:12 PM - SEC Filing
Aurinia settles patent dispute with Teva over generic voclosporin
August 19, 2026 4:05 PM - StreetInsider
Aurinia Settles Patent Litigation with Teva
August 19, 2026 4:05 PM - BizWire
Aurinia Pharmaceuticals (AUPH) PT Raised to $16 at RBC Capital
August 7, 2026 7:14 AM - StreetInsider
Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 5c
August 6, 2026 8:22 AM - StreetInsider
Form 10-Q Aurinia Pharmaceuticals For: Jun 30
August 6, 2026 8:17 AM - SEC Filing
Form 8-K Aurinia Pharmaceuticals For: Aug 06
August 6, 2026 8:03 AM - SEC Filing
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
August 6, 2026 8:00 AM - BizWire
Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs
July 6, 2026 8:03 AM - StreetInsider
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
July 6, 2026 8:00 AM - BizWire
Full Article List
